0K16 Stock Chart & Stats
$14.58
$0.00(0.00%)
At close: 4:00 PM EDT
$14.58
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$14.58 - $14.58
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$384.59M
Enterprise Value$577.18
Total Cash (Recent Filing)$45.17M
Total Debt (Recent Filing)$164.80M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding65,854,750
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside2.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$330.45M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~67% gross margins indicate durable product-level economics for Jeuveau and related injectables. High margins provide structural capacity to fund sales/marketing and international expansion, and allow operating leverage to translate revenue growth into profit as volumes scale over the next 2–6 months and beyond.
Multi-year Revenue ScalingMaterial multi-year top-line growth reflects strong market adoption of Jeuveau and improving distribution. A rising revenue base supports operating leverage, makes investments in new product launches and international rollouts more sustainable, and lowers execution risk as the company targets mid-term profitability.
Portfolio & Strategic LicensingAdding ProFuelo and expanding injectable portfolio creates durable commercial optionality and extends addressable markets beyond neurotoxins. Peak >$100M potential for ProFuelo and expanded international Estyme/Profhilo deals diversify revenue streams and strengthen long-term commercial leverage.
Bears Say
Weak CapitalizationNegative shareholders' equity and increasing debt signal constrained financial flexibility and higher leverage. This structural capital weakness elevates refinancing and interest risks, may limit strategic investment capacity, and increases vulnerability if cash generation stalls or market conditions worsen.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business still consumes liquidity despite narrowing losses. Reliance on credit facilities and external financing increases execution risk, constrains discretionary spending, and makes sustained investment and international scaling contingent on turning cash flow positive.
Product ConcentrationRevenue remains heavily concentrated in the toxin franchise, leaving Evolus exposed to competitive, pricing, or regulatory shifts in that category. While HA and new assets are scaling, limited diversification heightens single-product risk until other lines materially contribute to revenue mix.
Evolus News
0K16 FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest share price was $14.58 and its highest was $14.58 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $384.59M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Nov 10, 2026 which is in 95 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Aug 05, 2026. The company reported $0.007 earnings per share for the quarter, beating the consensus estimate of -$0.033 by $0.04.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Evolus Inc dividends here
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.07.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 65,854,750 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of $0.007 in its last earnings report, beating expectations of -$0.033. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in GB:0K16
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (2.88% Upside)
$15.00 (2.88% Upside)
Blogger Sentiment
Bullish
GB:0K16 Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
0K16 Company Deck
0K16 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational momentum: double-digit top-line growth (21% in Q2, 14% year-to-date), third consecutive quarter of positive adjusted EBITDA, expanded international presence, new strategic licensing (ProFuelo) and an upwardly revised full-year revenue and margin outlook. These positives were tempered by sequential increases in operating expenses, modest absolute adjusted EBITDA, a decline in cash versus the prior quarter and ongoing tariff uncertainty that requires inventory repositioning. Given the company’s raised guidance, profitable growth trajectory, and strategic partnerships that expand the product portfolio, the highlights materially outweigh the lowlights.View all GB:0K16 earnings summaries0K16 Stock 12 Month Forecast
Average Price Target
$15.00
▲(2.88% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―